New horizons for obsessive-compulsive disorder drug discovery: is targeting glutamate receptors the answer?

References

• van Roessel PJ, Grassi G, Aboujaoude EN, et al. Treatment-resistant OCD: pharmacotherapies in adults. Compr Psychiatry. 2023;120:152352. doi: 10.1016/j.comppsych.2022.152352
   PubMed Web of Science ®Google Scholar
• Perani D, Garibotto V, Gorini A, et al. In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder. Neuroimage. 2008;42(1):306–314. doi: 10.1016/j.neuroimage.2008.04.233
   PubMed Web of Science ®Google Scholar
• de Salles Andrade JB, Ferreira FM, Suo C, et al. An MRI study of the metabolic and structural abnormalities in obsessive-compulsive disorder. Front Hum Neurosci. 2019;13. doi: 10.3389/fnhum.2019.00186
   PubMedGoogle Scholar
• Karthik S, Sharma LP, Narayanaswamy JC, et al. Investigating the role of glutamate in obsessive-compulsive disorder: current perspectives. In: Neuropsychiatric disease and treatment. Vol. 16. Dove Medical Press Ltd; 2020. p. 1003–1013. doi: 10.2147/NDT.S211703
   Google Scholar
• Biria M, Banca P, Healy MP, et al. Cortical glutamate and GABA are related to compulsive behaviour in individuals with obsessive compulsive disorder and healthy controls. Nat Commun. 2023;14(1). doi: 10.1038/s41467-023-38695-z
   PubMedGoogle Scholar
• O’Neill J, Lai TM, Sheen C, et al. Cingulate and thalamic metabolites in obsessive-compulsive disorder. Psychiatry Res - Neuroimaging. 2016;254:34–40. doi: 10.1016/j.pscychresns.2016.05.005
   PubMed Web of Science ®Google Scholar
• Parmar A, Sharan P, Khandelwal SK, et al. Brain neurochemistry in unmedicated obsessive–compulsive disorder patients and effects of 12-week escitalopram treatment: 1H-magnetic resonance spectroscopy study. Psychiatry Clin Neurosci. 2019;73(7):386–393. doi: 10.1111/pcn.12850
   PubMedGoogle Scholar
• Whiteside SP, Port JD, Deacon BJ, et al. A magnetic resonance spectroscopy investigation of obsessive–compulsive disorder and anxiety. Psychiatry Res: Neuroimaging. 2006;146(2):137–147. doi: 10.1016/j.pscychresns.2005.12.006
   PubMed Web of Science ®Google Scholar
• Rosenberg DR, Macmaster FP, Keshavan MS, et al. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry. 2000;39(9):1096–1103. doi: 10.1097/00004583-200009000-00008
   PubMed Web of Science ®Google Scholar
• Biria M, Banca P, Keser E, et al. Excessive checking in obsessive-compulsive disorder: neurochemical correlates revealed by 7T magnetic resonance spectroscopy. Biol Psychiatry Global Open Sci. 1722;4(1):363–373. doi: 10.1016/j.bpsgos.2023.08.009
   Google Scholar
• Yücel M, Wood SJ, Wellard RM, et al. Anterior cingulate glutamate–glutamine levels predict symptom severity in women with obsessive–compulsive disorder. Aust N Z J Psychiatry. 2008;42(6):467–477. doi: 10.1080/00048670802050546
   PubMed Web of Science ®Google Scholar
• Akkus F, Terbeck S, Ametamey SM, et al. Metabotropic glutamate receptor 5 binding in patients with obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2014;17(12):1915–1922. doi: 10.1017/S1461145714000716
   PubMedGoogle Scholar
• Zhu Y, Fan Q, Han X, et al. Decreased thalamic glutamate level in unmedicated adult obsessive-compulsive disorder patients detected by proton magnetic resonance spectroscopy. J Affect Disord. 2015;178:193–200. doi: 10.1016/j.jad.2015.03.008
   PubMedGoogle Scholar
• Starck G, Ljungberg M, Nilsson M, et al. A 1H magnetic resonance spectroscopy study in adults with obsessive compulsive disorder: relationship between metabolite concentrations and symptom severity. J Neural Transm. 2008;115(7):1051–1062. doi: 10.1007/s00702-008-0045-4
   PubMed Web of Science ®Google Scholar
• Fan S, Cath DC, van den Heuvel OA, et al. Abnormalities in metabolite concentrations in tourette’s disorder and obsessive-compulsive disorder—A proton magnetic resonance spectroscopy study. Psychoneuroendocrinology. 2017;77:211–217. doi: 10.1016/j.psyneuen.2016.12.007
   PubMedGoogle Scholar
• Bédard MJ, Chantal S. Brain magnetic resonance spectroscopy in obsessive–compulsive disorder: the importance of considering subclinical symptoms of anxiety and depression. Psychiatry Res: Neuroimaging. 2011;192(1):45–54. doi: 10.1016/j.pscychresns.2010.10.008
   Google Scholar
• Brennan BP, Tkachenko O, Schwab ZJ, et al. An examination of rostral anterior cingulate cortex function and neurochemistry in obsessive-compulsive disorder. Neuropsychopharmacology. 2015;40(8):1866–1876. doi: 10.1038/npp.2015.36
   PubMedGoogle Scholar
• Li Y, Zhang CC, Weidacker K, et al. Investigation of anterior cingulate cortex gamma-aminobutyric acid and glutamate-glutamine levels in obsessive-compulsive disorder using magnetic resonance spectroscopy. BMC Psychiatry. 2019;19(1). doi: 10.1186/s12888-019-2160-1
   Google Scholar
• Zheng H, Yang W, Zhang B, et al. Reduced anterior cingulate glutamate of comorbid skin-picking disorder in adults with obsessive-compulsive disorder. J Affect Disord. 2020;265:193–199. doi: 10.1016/j.jad.2020.01.059
   PubMedGoogle Scholar
• Simpson HB, Kegeles LS, Hunter L, et al. Assessment of glutamate in striatal subregions in obsessive-compulsive disorder with proton magnetic resonance spectroscopy. Psychiatry Res - Neuroimaging. 2015;232(1):65–70. doi: 10.1016/j.pscychresns.2015.01.009
   Google Scholar
• Weber AM, Soreni N, Stanley JA, et al. Proton magnetic resonance spectroscopy of prefrontal white matter in psychotropic naïve children and adolescents with obsessive–compulsive disorder. Psychiatry Res: Neuroimaging. 2014;222(1–2):67–74. doi: 10.1016/j.pscychresns.2014.02.004
   Google Scholar
• Simpson HB, Shungu DC, Bender J, et al. Investigation of cortical glutamate-glutamine and γ-aminobutyric acid in obsessive-compulsive disorder by proton magnetic resonance spectroscopy. Neuropsychopharmacology. 2012;37(12):2684–2692. doi: 10.1038/npp.2012.132
   PubMedGoogle Scholar
• Batistuzzo MC, Sottili BA, Shavitt RG, et al. Lower ventromedial prefrontal cortex glutamate levels in patients with obsessive–compulsive disorder. Front Psychiatry. 2021;12. doi: 10.3389/fpsyt.2021.668304
   Google Scholar
• Naaijen J, Zwiers MP, Amiri H, et al. Fronto-striatal glutamate in autism spectrum disorder and obsessive compulsive disorder. Neuropsychopharmacology. 2017;42(12):2456–2465. doi: 10.1038/npp.2016.260
   PubMedGoogle Scholar
• Ortiz AE, Ortiz AG, Falcon C, et al. 1H-MRS of the anterior cingulate cortex in childhood and adolescent obsessive-compulsive disorder: a case-control study. Eur Neuropsychopharmacol. 2015;25(1):60–68. doi: 10.1016/j.euroneuro.2014.11.007
   PubMedGoogle Scholar
• Rosenberg DR, Mirza Y, Russell A, et al. Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry. 2004;43(9):1146–1153. doi: 10.1097/01.chi.0000132812.44664.2d
   PubMed Web of Science ®Google Scholar
• Giménez M, Cano M, Martínez-Zalacaín I, et al. Is glutamate associated with fear extinction and cognitive behavior therapy outcome in OCD? A pilot study. Eur Arch Psychiatry Clin Neurosci. 2020;270(8):1003–1014. doi: 10.1007/s00406-019-01056-3
   PubMedGoogle Scholar
• O’Neill J, Piacentini J, Chang S, et al. Glutamate in pediatric obsessive-compulsive disorder and response to cognitive-behavioral therapy: randomized clinical trial. Neuropsychopharmacology. 2017;42(12):2414–2422. doi: 10.1038/npp.2017.77
   PubMed Web of Science ®Google Scholar
• O’Neill J, Piacentini JC, Chang S, et al. MRSI correlates of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2012;36(1):161–168. doi: 10.1016/j.pnpbp.2011.09.007
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Khanna S, Chakrabarty K, et al. Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder. Neuropsychopharmacology. 2009;34(12):2489–2496. doi: 10.1038/npp.2009.77
   PubMed Web of Science ®Google Scholar
• Chakrabarty K, Bhattacharyya S, Christopher R, et al. Glutamatergic dysfunction in OCD. Neuropsychopharmacology. 2005;30(9):1735–1740. doi: 10.1038/sj.npp.1300733
   PubMed Web of Science ®Google Scholar
• Hanna GL, Veenstra-VanderWeele J, Cox NJ, et al. Genome-wide linkage analysis of families with obsessive-compulsive disorder ascertained through pediatric probands. Am J Med Genet - Neuropsychiatr Genet. 2002;114(5):541–552. doi: 10.1002/ajmg.10519
   Google Scholar
• Rajendram R, Kronenberg S, Burton CL, et al. Glutamate genetics in obsessive-compulsive disorder: a review. J Can Acad Child Adolesc Psychiatry. 2017;26(3):205–213. doi: 10.1038/npp.2015.26
   PubMed Web of Science ®Google Scholar
• Veenstra-Vanderweele J, Kim SJ, Gonen D, et al. Genomic organization of the SLC1A1/EAAC1 gene and mutation screening in early-onset obsessive-compulsive disorder. Mol Psychiatry. 2001;6(2):160–167. doi: 10.1038/sj.mp.4000806
   PubMedGoogle Scholar
• Arnold PD, Sicard T, Burroughs E, et al. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry. 2006;63(7):769. doi: 10.1001/archpsyc.63.7.769
   PubMed Web of Science ®Google Scholar
• Dickel DE, Veenstra-VanderWeele J, Cox NJ, et al. Association testing of the positional and functional Candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Arch Gen Psychiatry. 2006;63(7):778. doi: 10.1001/archpsyc.63.7.778
   PubMed Web of Science ®Google Scholar
• Samuels J, Wang Y, Riddle MA, et al. Comprehensive family-based association study of the glutamate transporter gene SLC1A1 in obsessive-compulsive disorder. Am J Med Genet Pt B. 2011;156(4):472–477. doi: 10.1002/ajmg.b.31184
   Google Scholar
• Shugart YY, Wang Y, Samuels JF, et al. A family-based association study of the glutamate transporter gene SLC1A1 in obsessive–compulsive disorder in 378 families. Am J Med Genet Pt B. 2009;150(6):886–892. doi: 10.1002/ajmg.b.30914
   Google Scholar
• Stewart SE, Fagerness JA, Platko J, et al. Association of the SLC1A1 glutamate transporter gene and obsessive-compulsive disorder. Am J Med Genet Pt B. 2007;144B(8):1027–1033. doi: 10.1002/ajmg.b.30533
   PubMed Web of Science ®Google Scholar
• Wendland JR, Moya PR, Timpano KR, et al. A haplotype containing quantitative trait loci for SLC1A1 gene expression and its association with obsessive-compulsive disorder. Arch Gen Psychiatry. 2009;66(4):408. doi: 10.1001/archgenpsychiatry.2009.6
   PubMed Web of Science ®Google Scholar
• Wu H, Wang X, Xiao Z, et al. Association between SLC1A1 gene and early-onset OCD in the han Chinese population: a case–control study. J Mol Neurosci. 2013;50(2):353–359. doi: 10.1007/s12031-013-9995-6
   PubMedGoogle Scholar
• Kwon JS, Joo YH, Nam HJ, et al. Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics–induced obsessive-compulsive symptoms. Arch Gen Psychiatry. 2009;66(11):1233. doi: 10.1001/archgenpsychiatry.2009.155
   PubMed Web of Science ®Google Scholar
• Wang Y, Adamczyk A, Shugart YY, et al. A screen of SLC1A1 for ocd-related alleles. Am J Med Genet Pt B. 2010;153(2):675–679. doi: 10.1002/ajmg.b.31001
   Google Scholar
• Mattheisen M, Samuels JF, Wang Y, et al. Genome-wide association study in obsessive-compulsive disorder: results from the OCGAS. Mol Psychiatry. 2015;20(3):337–344. doi: 10.1038/mp.2014.43
   PubMed Web of Science ®Google Scholar
• Burton CL, Lemire M, Xiao B, et al. Genome-wide association study of pediatric obsessive-compulsive traits: shared genetic risk between traits and disorder. Transl Psychiatry. 2021;11(1). doi: 10.1038/s41398-020-01121-9
   PubMedGoogle Scholar
• Alonso P, Gratacós M, Segalàs C, et al. Association between the NMDA glutamate receptor GRIN2B gene and obsessive-compulsive disorder. J Psychiatry Neurosci. 2012;37(4):273–281. doi: 10.1503/jpn.110109
   PubMed Web of Science ®Google Scholar
• Arnold PD, Rosenberg DR, Mundo E, et al. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl). 2004;174(4):530–538. doi: 10.1007/s00213-004-1847-1
   PubMed Web of Science ®Google Scholar
• Kohlrausch FB, Giori IG, Melo-Felippe FB, et al. Association of GRIN2B gene polymorphism and obsessive compulsive disorder and symptom dimensions: a pilot study. Psychiatry Res. 2016;243:152–155. doi: 10.1016/j.psychres.2016.06.027
   PubMedGoogle Scholar
• Delorme R, Krebs M-O, Chabane N, et al. Frequency and transmission of glutamate receptors GRIK2 and GRIK3 polymorphisms in patients with obsessive compulsive disorder. Neuroreport. 2004;15(4):699–702. doi: 10.1097/00001756-200403220-00025
   PubMedGoogle Scholar
• Sampaio AS, Fagerness J, Crane J, et al. Association between polymorphisms in GRIK2 gene and obsessive-compulsive disorder: a family-based study. CNS Neurosci Ther. 2011;17(3):141–147. doi: 10.1111/j.1755-5949.2009.00130.x
   PubMedGoogle Scholar
• Boardman L, van der Merwe L, Lochner C, et al. Investigating SAPAP3 variants in the etiology of obsessive-compulsive disorder and trichotillomania in the South African white population. Compr Psychiatry. 2011;52(2):181–187. doi: 10.1016/j.comppsych.2010.05.007
   PubMed Web of Science ®Google Scholar
• Stewart SE, Yu D, Scharf JM, et al. Genome-wide association study of obsessive-compulsive disorder. Mol Psychiatry. 2013;18(7):788–798. doi: 10.1038/mp.2012.85
   PubMed Web of Science ®Google Scholar
• Züchner S, Wendland JR, Ashley-Koch AE, et al. Multiple rare SAPAP3 missense variants in trichotillomania and OCD. Mol Psychiatry. 2009;14(1):6–9. doi: 10.1038/mp.2008.83
   PubMed Web of Science ®Google Scholar
• Gazzellone MJ, Zarrei M, Burton CL, et al. Uncovering obsessive-compulsive disorder risk genes in a pediatric cohort by high-resolution analysis of copy number variation. J Neurodev Disord. 2016;8(1). doi: 10.1186/s11689-016-9170-9
   PubMedGoogle Scholar
• Wilson C, Gattuso JJ, Hannan AJ, et al. Mechanisms of pathogenesis and environmental moderators in preclinical models of compulsive-like behaviours. Neurobiol Dis. 2023;185:106223. doi: 10.1016/j.nbd.2023.106223
   PubMedGoogle Scholar
• Welch JM, Wang D, Feng G. Differential mRNA expression and protein localization of the SAP90/PSD-95-Associated proteins (SAPAPs) in the nervous system of the mouse. J Comp Neurol. 2004;472(1):24–39. doi: 10.1002/cne.20060
   PubMedGoogle Scholar
• Hadjas LC, Schartner MM, Cand J, et al. Projection-specific deficits in synaptic transmission in adult Sapap3-knockout mice. Neuropsychopharmacology. 2020;45(12):2020–2029. doi: 10.1038/s41386-020-0747-3
   PubMedGoogle Scholar
• Xu P, Grueter BA, Britt JK, et al. Double deletion of melanocortin 4 receptors and SAPAP3 corrects compulsive behavior and obesity in mice. Proc Natl Acad Sci U S A. 2013;110(26):10759–10764. doi: 10.1073/pnas.1308195110
   PubMed Web of Science ®Google Scholar
• Lamothe H, Schreiweis C, Mondragón-González LS, et al. The Sapap3−/− mouse reconsidered as a comorbid model expressing a spectrum of pathological repetitive behaviours. Transl Psychiatry. 2023;13(1). doi: 10.1038/s41398-023-02323-7
   PubMedGoogle Scholar
• Welch JM, Lu J, Rodriguiz RM, et al. Cortico-striatal synaptic defects and ocd-like behaviours in Sapap3-mutant mice. Nature. 2007;448(7156):894–900. doi: 10.1038/nature06104
   PubMed Web of Science ®Google Scholar
• Manning EE, Wang AY, Saikali LM, et al. Disruption of prepulse inhibition is associated with compulsive behavior severity and nucleus accumbens dopamine receptor changes in Sapap3 knockout mice. Sci Rep. 2021;11(1). doi: 10.1038/s41598-021-88769-5
   Google Scholar
• Manning EE, Dombrovski AY, Torregrossa MM, et al. Impaired instrumental reversal learning is associated with increased medial prefrontal cortex activity in Sapap3 knockout mouse model of compulsive behavior. Neuropsychopharmacology. 2019;44(8):1494–1504. doi: 10.1038/s41386-018-0307-2
   PubMedGoogle Scholar
• Ehmer I, Feenstra M, Willuhn I, et al. Instrumental learning in a mouse model for obsessive-compulsive disorder: impaired habit formation in Sapap3 mutants. Neurobiol Learn Mem. 2020;168:168. doi: 10.1016/j.nlm.2020.107162
   Google Scholar
• Burguière E, Monteiro P, Feng G, et al. Optogenetic stimulation of lateral orbitofronto-striatal pathway suppresses compulsive behaviors. Science. 2013;340(6137):1243–1246. doi: 10.1126/science.1232380
   PubMed Web of Science ®Google Scholar
• Davis GL, Minerva AR, Lario A, et al. Ketamine increases activity of a fronto-striatal projection that regulates compulsive behavior in SAPAP3 knockout mice. Nat Commun. 2021;12(1):6040. doi: 10.1038/s41467-021-26247-2
   PubMedGoogle Scholar
• Ho EV, Welch A, Thompson SL, et al. Mice lacking Ptprd exhibit deficits in goal-directed behavior and female-specific impairments in sensorimotor gating. PLoS One. 2023;18(5):e0277446. doi: 10.1371/journal.pone.0277446
   PubMedGoogle Scholar
• Shmelkov SV, Hormigo A, Jing D, et al. Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive–like behaviors in mice. Nat Med. 2010;16(5):598–602. doi: 10.1038/nm.2125
   PubMed Web of Science ®Google Scholar
• Campbell KM, de Lecea L, Severynse DM, et al. OCD-Like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1 neurons. J Neurosci. 1999;19(12):5044–5053. doi: 10.1523/JNEUROSCI.19-12-05044.1999
   PubMed Web of Science ®Google Scholar
• Zike ID, Chohan MO, Kopelman JM, et al. OCD candidate gene SLC1A1/EAAT3 impacts basal ganglia-mediated activity and stereotypic behavior. Proc Natl Acad Sci U S A. 2017;114(22):5719–5724. doi: 10.1073/pnas.1701736114
   PubMedGoogle Scholar
• González LF, Henríquez-Belmar F, Delgado-Acevedo C, et al. Neurochemical and behavioral characterization of neuronal glutamate transporter EAAT3 heterozygous mice. Biol Res. 2017;50(1). doi: 10.1186/s40659-017-0138-3
   PubMedGoogle Scholar
• Grados M, Prazak M, Saif A, et al. A review of animal models of obsessive-compulsive disorder: a focus on developmental, immune, endocrine and behavioral models. Expert Opin Drug Discov. 2016;11(1):27–43). Taylor and Francis Ltd. 10.1517/17460441.2016.1103225
   PubMed Web of Science ®Google Scholar
• Ryan TJ, Kopanitsa MV, Indersmitten T, et al. Evolution of GluN2A/B cytoplasmic domains diversified vertebrate synaptic plasticity and behavior. Nat Neurosci. 2013;16(1):25–32. doi: 10.1038/nn.3277
   PubMed Web of Science ®Google Scholar
• Brigman JL, Wright T, Talani G, et al. Loss of GluN2B-Containing NMDA receptors in CA1 hippocampus and cortex impairs long-term depression, reduces dendritic spine density, and disrupts learning. J Neurosci. 2010;30(13):4590–4600. doi: 10.1523/JNEUROSCI.0640-10.2010
   PubMed Web of Science ®Google Scholar
• Wang C-C, Held RG, Chang S-C, et al. A critical role for GluN2B-Containing NMDA receptors in cortical development and function. Neuron. 2011;72(5):789–805. doi: 10.1016/j.neuron.2011.09.023
   PubMed Web of Science ®Google Scholar
• von Engelhardt J, Doganci B, Jensen V, et al. Contribution of hippocampal and extra-hippocampal NR2B-Containing NMDA receptors to performance on spatial learning tasks. Neuron. 2008;60(5):846–860. doi: 10.1016/j.neuron.2008.09.039
   PubMed Web of Science ®Google Scholar
• Pauls DL, Abramovitch A, Rauch SL, et al. Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective. Nat Rev Neurosci. 2014;15(6):410–424. doi: 10.1038/nrn3746.
   PubMed Web of Science ®Google Scholar
• Vlček P, Polák J, Brunovský M, et al. Role of glutamatergic system in obsessive-compulsive disorder with possible therapeutic implications [published correction appears in pharmacopsychiatry. 2018 Nov;51(6): e3. doi: 10.1055/s-0043-121511]. Pharmacopsychiatry. 2018;51(6):229–242. doi: 10.1055/s-0043-121511
   PubMedGoogle Scholar
• Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol. 2009;29(1):51–55. doi: 10.1097/JCP.0b013e318192e9a4
   PubMed Web of Science ®Google Scholar
• Bakhla AK, Verma V, Soren S, et al. An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder. Ind Psychiatry J. 2013;22(2):149–152. doi: 10.4103/0972-6748.132930
   PubMedGoogle Scholar
• Feusner JD, Kerwin L, Saxena S, et al. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacol Bull. 2009;42(1):81–93.
   PubMed Web of Science ®Google Scholar
• Pasquini M, Biondi M. Memantine augmentation for refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(6):1173–1175. doi: 10.1016/j.pnpbp.2006.04.013
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Weizman R, Weizman A, et al. Memantine for treatment-resistant OCD. Am J Psychiatry. 2005;162(11):2191–2192. doi: 10.1176/appi.ajp.162.11.2191-a
   PubMed Web of Science ®Google Scholar
• Stewart SE, Jenike EA, Hezel DM, et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol. 2010;30(1):34–39. doi: 10.1097/JCP.0b013e3181c856de
   PubMed Web of Science ®Google Scholar
• Farnia V, Gharehbaghi H, Alikhani M, et al. Efficacy and tolerability of adjunctive gabapentin and memantine in obsessive compulsive disorder: double-blind, randomized, placebo-controlled trial. J Psychiatr Res. 2018;104:137–143. doi: 10.1016/j.jpsychires.2018.07.008
   PubMed Web of Science ®Google Scholar
• Haghighi M, Jahangard L, Mohammad-Beigi H, et al. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology (Berl). 2013;228(4):633–640. doi: 10.1007/s00213-013-3067-z
   PubMed Web of Science ®Google Scholar
• Ghaleiha A, Entezari N, Modabbernia A, et al. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res. 2013;47(2):175–180. doi: 10.1016/j.jpsychires.2012.09.015
   PubMed Web of Science ®Google Scholar
• Askari S, Mokhtari S, Shariat SV, et al. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial. BMC Psychiatry. 2022 Jan 12;22(1):34. Published 2022. doi: 10.1186/s12888-021-03642-z
   PubMedGoogle Scholar
• Modarresi A, Sayyah M, Razooghi S, et al. Memantine augmentation improves symptoms in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a randomized controlled trial. Pharmacopsychiatry. 2018;51(6):263–269. doi: 10.1055/s-0043-120268
   PubMed Web of Science ®Google Scholar
• Modarresi A, Chaibakhsh S, Koulaeinejad N, et al. A systematic review and meta-analysis: memantine augmentation in moderate to severe obsessive-compulsive disorder. Psychiatry Res. 2019;282:112602. doi: 10.1016/j.psychres.2019.112602
   PubMed Web of Science ®Google Scholar
• Grant JE, Chesivoir E, Valle S, et al. Double-blind placebo-controlled study of memantine in trichotillomania and skin-picking disorder. Am J Psychiatry. 2023;180(5):348–356. doi: 10.1176/appi.ajp.20220737
   PubMedGoogle Scholar
• Anand A, Mathew SJ, Sanacora G, et al. Ketamine versus ECT for nonpsychotic treatment-resistant major depression. N Engl J Med. 2023;388(25):2315–2325. doi: 10.1056/NEJMoa2302399
   PubMed Web of Science ®Google Scholar
• Rodriguez CI, Kegeles LS, Flood P, et al. Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2011;72(4):567–569. doi: 10.4088/JCP.10l06653
   PubMed Web of Science ®Google Scholar
• Rodriguez CI, Kegeles LS, Levinson A, et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. 2013;38(12):2475–2483. doi: 10.1038/npp.2013.150
   PubMed Web of Science ®Google Scholar
• Rodriguez CI, Kegeles LS, Levinson A, et al. In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: proof of concept. Psychiatry Res. 2015;233(2):141–147. doi: 10.1016/j.pscychresns.2015.06.001
   PubMed Web of Science ®Google Scholar
• Sharma LP, Thamby A, Balachander S, et al. Clinical utility of repeated intravenous ketamine treatment for resistant obsessive-compulsive disorder. Asian J Psychiatr. 2020;52:102183. doi: 10.1016/j.ajp.2020.102183
   PubMedGoogle Scholar
• Bloch MH, Wasylink S, Landeros-Weisenberger A, et al. Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry. 2012;72(11):964–970. doi: 10.1016/j.biopsych.2012.05.028
   PubMed Web of Science ®Google Scholar
• Niciu MJ, Grunschel BD, Corlett PR, et al. Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder. J Psychopharmacol. 2013;27(7):651–654. doi: 10.1177/0269881113486718
   PubMed Web of Science ®Google Scholar
• Adams TG, Bloch MH, Pittenger C. Intranasal ketamine and cognitive-behavioral therapy for treatment-refractory obsessive-compulsive disorder. J Clin Psychopharmacol. 2017;37(2):269–271. doi: 10.1097/JCP.0000000000000659
   PubMed Web of Science ®Google Scholar
• Rodriguez CI, Lapidus KAB, Zwerling J, et al. Challenges in testing intranasal ketamine in obsessive-compulsive disorder. J Clin Psychiatry. 2017;78(4):466–467. doi: 10.4088/JCP.16cr11234
   PubMed Web of Science ®Google Scholar
• Rodriguez CI, Wheaton M, Zwerling J, et al. Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial. J Clin Psychiatry. 2016;77(3):408–409. doi: 10.4088/JCP.15l10138
   PubMed Web of Science ®Google Scholar
• Rodriguez CI, Levinson A, Zwerling J, et al. Open-label trial on the effects of memantine in adults with obsessive-compulsive disorder after a single ketamine infusion. J Clin Psychiatry. 2016;77(5):688–689. doi: 10.4088/JCP.15l10318
   PubMed Web of Science ®Google Scholar
• Alves-Pereira R, Fontes M, Cordeiro V, et al. Esketamine augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective chart review. Clin Neuropharmacol. 2024;47(1):17–21. doi: 10.1097/WNF.0000000000000578
   PubMedGoogle Scholar
• Matteo M, Cristian P, Laura M, et al. The use of esketamine in comorbid treatment resistant depression and obsessive compulsive disorder following extensive pharmacogenomic testing: a case report. Ann Gen Psychiatry. 2021;20(1):43. doi: 10.1186/s12991-021-00365-z
   PubMed Web of Science ®Google Scholar
• Kaltenboeck A, Foerster E, Strafner S, et al. Clinical case report: considerable improvement of severe and difficult-to-treat obsessive-compulsive disorder with comorbid depression under treatment with esketamine and concomitant psychotherapy. Front Psychiatry. 2023 [cited 2023 Nov 28];14:1291077. doi: 10.3389/fpsyt.2023.1291077
   PubMedGoogle Scholar
• Stryjer R, Budnik D, Ebert T, et al. Amantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs-an open-label study. Clin Neuropharmacol. 2014;37(3):79–81. doi: 10.1097/WNF.0000000000000029
   PubMed Web of Science ®Google Scholar
• Naderi S, Faghih H, Aqamolaei A, et al. Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control. Psychiatry Clin Neurosci. 2019;73(4):169–174. doi: 10.1111/pcn.12803
   PubMedGoogle Scholar
• Miranda AS, Miranda AS, Teixeira AL. Lamotrigine as a mood stabilizer: insights from the pre-clinical evidence. Expert Opin Drug Discov. 2019;14(2):179–190. doi: 10.1080/17460441.2019.1553951
   PubMed Web of Science ®Google Scholar
• Bruno A, Micò U, Pandolfo G, et al. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol. 2012;26(11):1456–1462. doi: 10.1177/0269881111431751
   PubMed Web of Science ®Google Scholar
• Khalkhali M, Aram S, Zarrabi H, et al. Lamotrigine augmentation versus placebo in serotonin reuptake inhibitors-resistant obsessive-compulsive disorder: a randomized controlled trial. Iran J Psychiatry. 2016;11(2):104–114.
   PubMedGoogle Scholar
• Suhas S, Malo PK, Kumar V, et al. Treatment strategies for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a network meta-analysis of randomised controlled trials. World J Biol Psychiatry. 2023;24(2):162–177. doi: 10.1080/15622975.2022.2082525
   PubMedGoogle Scholar
• Mowla A, Khajeian AM, Sahraian A, et al. Topiramate augmentation in resistant OCD: a double-blind placebo-controlled clinical trial. CNS Spectr. 2010;15(11):613–617. doi: 10.1017/S1092852912000065
   PubMed Web of Science ®Google Scholar
• Berlin HA, Koran LM, Jenike MA, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2011;72(5):716–721. doi: 10.4088/JCP.09m05266gre
   PubMed Web of Science ®Google Scholar
• Afshar H, Akuchekian S, Mahaky B, et al. Topiramate augmentation in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Res Med Sci. 2014;19(10):976–981.
   PubMed Web of Science ®Google Scholar
• Coric V, Taskiran S, Pittenger C, et al. Riluzole augmentation in treatment-resistant obsessive–compulsive disorder: an open-label trial. Biol Psychiatry. 2005;58(5):424–428. doi: 10.1016/j.biopsych.2005.04.043
   PubMed Web of Science ®Google Scholar
• Coric V, Milanovic S, Wasylink S, et al. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (Berl). 2003;167(2):219–220. doi: 10.1007/s00213-003-1396-z
   PubMedGoogle Scholar
• Pittenger C, Kelmendi B, Wasylink S, et al. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-up. J Clin Psychopharmacol. 2008;28(3):363–367. doi: 10.1097/JCP.0b013e3181727548
   PubMedGoogle Scholar
• Pittenger C, Bloch MH, Wasylink S, et al. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial. J Clin Psychiatry. 2015;76(8):1075–1084. doi: 10.4088/JCP.14m09123
   PubMed Web of Science ®Google Scholar
• Emamzadehfard S, Kamaloo A, Paydary K, et al. Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci. 2016;70(8):332–341. doi: 10.1111/pcn.12394
   PubMed Web of Science ®Google Scholar
• Grant P, Lougee L, Hirschtritt M, et al. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2007;17(6):761–767. doi: 10.1089/cap.2007.0021
   PubMed Web of Science ®Google Scholar
• Grant PJ, Joseph LA, Farmer CA, et al. 12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive–compulsive disorder. Neuropsychopharmacology. 2014;39(6):1453–1459. doi: 10.1038/npp.2013.343
   PubMed Web of Science ®Google Scholar
• Aguiar L. Adjunctive troriluzole, a novel glutamate modulator, in patients with obsessive-compulsive disorder: impact of baseline disease severity on treatment outcomes. CNS summit 2021: abstracts of poster presentations. (2021). Innov Clin Neurosci. 2021;18(10–12 Suppl 1):S5–S16.
   Google Scholar
• Oulis P, Mourikis I, Konstantakopoulos G. Pregabalin augmentation in treatment-resistant obsessive–compulsive disorder. Int Clin Psychopharmacol. 2011;26(4):221–224. doi: 10.1097/YIC.0b013e3283466657
   PubMedGoogle Scholar
• Mowla A, Ghaedsharaf M. Pregabalin augmentation for resistant obsessive-compulsive disorder: a double-blind placebo-controlled clinical trial. CNS Spectr. 2020;25(4):552–556. doi: 10.1017/S1092852919001500
   PubMed Web of Science ®Google Scholar
• Rodriguez CI, Bender JJ, Marcus SM, et al. Minocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: an open-label trial. J Clin Psychiatry. 2010;71(9):1247–1249. doi: 10.4088/JCP.09l05805blu
   PubMed Web of Science ®Google Scholar
• Esalatmanesh S, Abrishami Z, Zeinoddini A, et al. Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: a placebo-controlled, double-blind, randomized trial. Psychiatry Clin Neurosci. 2016;70(11):517–526. doi: 10.1111/pcn.12430
   PubMed Web of Science ®Google Scholar
• Sarris J, Byrne G, Castle D, et al. N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: a phase III, 20-week, double-blind, randomized, placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2022;117:110550. doi: 10.1016/j.pnpbp.2022.110550
   PubMedGoogle Scholar
• Costa DLC, Diniz JB, Requena G, et al. Randomized, double-blind, placebo-controlled trial of N-Acetylcysteine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2017;78(7):e766–e773. doi: 10.4088/JCP.16m11101
   PubMed Web of Science ®Google Scholar
• Paydary K, Akamaloo A, Ahmadipour A, et al. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther. 2016;41(2):214–219. doi: 10.1111/jcpt.12370
   PubMed Web of Science ®Google Scholar
• Afshar H, Roohafza H, Mohammad-Beigi H, et al. N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2012;32(6):797–803. doi: 10.1097/JCP.0b013e318272677d
   PubMed Web of Science ®Google Scholar
• Greenberg WM, Benedict MM, Doerfer J, et al. Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults. J Psychiatr Res. 2009;43(6):664–670. doi: 10.1016/j.jpsychires.2008.10.007
   PubMed Web of Science ®Google Scholar
• Wu PL, Tang HS, Lane HY, et al. Sarcosine therapy for obsessive compulsive disorder: a prospective, open-label study. J Clin Psychopharmacol. 2011;31(3):369–374. doi: 10.1097/JCP.0b013e3182189878
   PubMed Web of Science ®Google Scholar
• Rodriguez CI, Zwerling J, Kalanthroff E, et al. Effect of a novel NMDA receptor modulator, Rapastinel (formerly GLYX-13), in OCD: proof of concept. Am J Psychiatry. 2016;173(12):1239–1241. doi: 10.1176/appi.ajp.2016.16080868
   PubMed Web of Science ®Google Scholar
• Tabuteau H, Jones A, Anderson A, et al. Effect of AXS-05 (dextromethorphan-bupropion) in Major depressive disorder: a randomized double-blind controlled trial. Am J Psychiatry. 2022;179(7):490–499. doi: 10.1176/appi.ajp.21080800
   PubMed Web of Science ®Google Scholar
• Iosifescu DV, Jones A, O’Gorman C, et al. Efficacy and safety of AXS-05 (dextromethorphan-bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (GEMINI). J Clin Psychiatry. 2022 [cited 2022 May 30];83(4):21m14345. doi: 10.4088/JCP.21m14345
   PubMed Web of Science ®Google Scholar
• Rech P, Custodio RM, Rodrigues Uggioni ML, et al. Use of nitrous oxide in the treatment of major depressive disorder and treatment-resistant major depressive disorder: a systematic review and meta-analysis nitrous oxide in depressive disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2024;129:110869. doi: 10.1016/j.pnpbp.2023.110869
   PubMedGoogle Scholar
• Grassi G, Cecchelli C, Vignozzi L, et al. Investigational and experimental drugs to treat obsessive-compulsive disorder. J Exp Pharmacol. 2021 [cited 2021 Jan 5];12:695–706. doi: 10.2147/JEP.S255375
   PubMedGoogle Scholar
• Grassi G, Pallanti S. Current and up-and-coming pharmacotherapy for obsessive-compulsive disorder in adults. Expert Opin Pharmacother. 2018;19(14):1541–1550. doi: 10.1080/14656566.2018.1528230
   PubMed Web of Science ®Google Scholar